Equity Profile

ORKA

Oruka Therapeutics, Inc.

Health CareBiotechnology$3.6B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the healthcare sector....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for signs of revenue growth as a measure of market demand for Oruka's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the healthcare sector. With a market cap of $4 billion, it plays a vital role in advancing treatments that could significantly impact patient care and health outcomes.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In Q1 2026, Oruka reported an EPS of -$0.48, beating expectations by 8.4%. However, the stock declined by 2.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continue to advance clinical trials for key therapies.
Focus on increasing operational efficiency.
Enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Overall expectations for Oruka's upcoming earnings are cautious, given the lack of analyst estimates and mixed historical performance.

Bull Case

If Oruka can demonstrate strong revenue growth and effective cost management, it could signal a positive turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to show improvement in profitability or revenue, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this number will be critical in assessing whether Oruka is maintaining its growth trajectory.

How much has Oruka invested in R&D this quarter?

R&D spending is crucial for future product development, and any significant changes could impact investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Oruka's potential for revenue growth due to its innovative pipeline, which could lead to stronger-than-expected performance.

Supporting Evidence

The company's history of beating EPS estimates suggests potential for positive surprises.

Investors may not fully appreciate the impact of recent partnerships on future revenue.

The options market indicates a significant move, suggesting that traders expect more volatility than the consensus reflects.

Key Risk

If R&D spending shows a substantial increase, it could signal a stronger commitment to future growth, contradicting current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Oruka's ability to balance investment in innovation with the need for improved financial performance.

Bull Confirmed If

An EPS of -$0.40 or better, along with a clear commitment to R&D investment.

Bear Confirmed If

An EPS worse than -$0.50, indicating ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±34.71%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$462,829.56

7,000 sh

1 insider

Net

$462,829.56

Net selling

Most Active Insiders· 3 open-market trades

Chief Medical OfficerGoncalves Joana
$462,829.56

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests a potential stock increase of around 2.31%, confirming positive investor sentiment.

In-Line / Cautious

A cautious inline report could lead to a muted response, reflecting ongoing concerns about the company's growth trajectory.

Miss

If the company misses expectations, the stock could decline significantly, with historical patterns suggesting a drop of around 2.27%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress for key therapies.
2Details on partnerships and collaborations that could enhance revenue.
3Insights into cost management strategies and operational efficiency.
4Comments on market demand for Oruka's products.
5Future guidance on R&D spending and its expected impact.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the healthcare sector....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for signs of revenue growth as a measure of market demand for Oruka's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In Q1 2026, Oruka reported an EPS of -$0.48, beating expectations by 8.4%. However, the stock declined by 2.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continue to advance clinical trials for key therapies.
Focus on increasing operational efficiency.
Enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Overall expectations for Oruka's upcoming earnings are cautious, given the lack of analyst estimates and mixed historical performance.

Bull Case

If Oruka can demonstrate strong revenue growth and effective cost management, it could signal a positive turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to show improvement in profitability or revenue, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this number will be critical in assessing whether Oruka is maintaining its growth trajectory.

How much has Oruka invested in R&D this quarter?

R&D spending is crucial for future product development, and any significant changes could impact investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Oruka's potential for revenue growth due to its innovative pipeline, which could lead to stronger-than-expected performance.

Supporting Evidence

The company's history of beating EPS estimates suggests potential for positive surprises.

Investors may not fully appreciate the impact of recent partnerships on future revenue.

The options market indicates a significant move, suggesting that traders expect more volatility than the consensus reflects.

Key Risk

If R&D spending shows a substantial increase, it could signal a stronger commitment to future growth, contradicting current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Oruka's ability to balance investment in innovation with the need for improved financial performance.

Bull Confirmed If

An EPS of -$0.40 or better, along with a clear commitment to R&D investment.

Bear Confirmed If

An EPS worse than -$0.50, indicating ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±34.71%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$462,829.56

7,000 sh

1 insider

Net

$462,829.56

Net selling

Most Active Insiders· 3 open-market trades

Chief Medical OfficerGoncalves Joana
$462,829.56

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests a potential stock increase of around 2.31%, confirming positive investor sentiment.

In-Line / Cautious

A cautious inline report could lead to a muted response, reflecting ongoing concerns about the company's growth trajectory.

Miss

If the company misses expectations, the stock could decline significantly, with historical patterns suggesting a drop of around 2.27%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress for key therapies.
2Details on partnerships and collaborations that could enhance revenue.
3Insights into cost management strategies and operational efficiency.
4Comments on market demand for Oruka's products.
5Future guidance on R&D spending and its expected impact.